Recommendations for cyclin-dependent kinase 4/6 inhibitor treatments in the context of co-morbidity and drug interactions (Review)

Sadeleştirilmiş öğe sayfası
dc.contributor.authorTeomete, Mehmet
dc.contributor.authorCabuk, Devrim
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorSeber, Selcuk
dc.contributor.authorOzturk, Ozge Fulya
dc.contributor.authorAver, Birkan
dc.contributor.authorKaraalp, Atila
dc.contributor.authorBasaran, Gul
dc.date.accessioned2025-10-16T15:13:35Z
dc.date.issued2024
dc.identifier.doi10.3892/ol.2024.14278
dc.identifier.otherWOS:001169395400001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/5875
dc.publisherSPANDIDOS PUBL LTD
dc.sourceONCOLOGY LETTERS
dc.subjectadvanced breast cancer
dc.subjectcomorbidity
dc.subjectcyclin\\-dependent kinase 4 and 6 inhibitors
dc.subjectsafety
dc.subjecttolerability
dc.subjecttoxicity
dc.titleRecommendations for cyclin-dependent kinase 4/6 inhibitor treatments in the context of co-morbidity and drug interactions (Review)
dc.typeReview

Dosyalar

Koleksiyonlar

WOS